Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease

Nephrology

Volumn 14, Issue 4, 2009, Pages 408-415

  Kovesdy, Csaba P ^a,b   Kalantar Zadeh, Kamyar ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acidosis; Anemia; Inflammation; Oxidative stress; Protein energy wasting; Renal osteodystrophy

Indexed keywords

ADIPONECTIN; ALBUMIN; AMYLOID A PROTEIN; BICARBONATE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POTASSIUM; PREALBUMIN; THYROID HORMONE; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; BONE MINERALIZATION; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONGENITAL MALFORMATION; DISEASE PREDISPOSITION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LYMPHOCYTE COUNT; METABOLIC ACIDOSIS; METABOLIC BONE DISEASE; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL; WASTING SYNDROME;

ANEMIA; BIOLOGICAL MARKERS; HUMANS; PROTEIN-ENERGY MALNUTRITION; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; SEVERITY OF ILLNESS INDEX;

EID: 67650745578     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01119.x     Document Type: Review

References (114)

1. Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC. Epidemiology of dialysis patients and heart failure patients. Semin. Nephrol. 2006 26 : 118 33.
2. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007 71 : 31 8.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004 15 : 2208 18.
4. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006 70 : 771 80.
5. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J. Am. Soc. Nephrol. 2002 13 : 2762 9.
6. Fellner SK, Lang RM, Neumann A, Bushinsky DA, Borow KM. Parathyroid hormone and myocardial performance in dialysis patients. Am. J. Kidney Dis. 1991 18 : 320 25.
7. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 2001 12 : 2131 8.
8. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002 62 : 1724 31.
9. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 2000 87 : E10 17.
10. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int. 2008 73 : 1355 63.
11. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transpl. 2000 15 : 1014 21.
12. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transpl. 2003 18 : 1731 40.
13. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000 342 : 1478 83.
14. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Battleground: Chronic kidney disorders mineral and bone disease - Calcium obsession, vitamin d, and binder confusion. Clin. J. Am. Soc. Nephrol. 2008 3 : 168 73.
15. Shinaberger CS, Greenland S, Kopple JD et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am. J. Clin. Nutr. 2008 88 : 1511 18.
16. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin. Nephrol. 2000 20 : 345 9.
17. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis. 1996 28 : 53 61. (Pubitemid 26231466)
18. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J. Am. Soc. Nephrol. 2000 11 : 335 42.
19. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 2006 17 : 1181 91.
20. Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr. Med. Res. Opin. 2006 22 : 1929 37.
21. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006 69 : 560 64.
22. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998 339 : 584 90.
23. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J. Am. Soc. Nephrol. 2005 16 : 2180 89.
24. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006 355 : 2085 98.
25. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006 355 : 2071 84.
26. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 2007 369 : 381 8.
27. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005 16 : 3070 80.
28. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol. Dial. Transpl. 2004 19 : 141 9.
29. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am. J. Kidney Dis. 2008 52 : 727 36.
30. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 74 : 791 8.
31. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin. J. Am. Soc. Nephrol. 2007 2 : 1274 82.
32. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008 3 : 1077 83.
33. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 1990 15 : 458 82.
34. Iseki K, Uehara H, Nishime K et al. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am. J. Kidney Dis. 1996 28 : 541 8.
35. Kovesdy CP, Regidor DL, Mehrotra R et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2007 2 : 999 1007.
36. Beddhu S, Kaysen GA, Yan G et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am. J. Kidney Dis. 2002 40 : 721 7.
37. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int. 1993 44 : 115 19.
38. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N et al. Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol. Dial. Transpl. 2005 20 : 1880 88.
39. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 1990 15 : 458 82.
40. Avram MM, Goldwasser P, Erroa M, Fein PA. Predictors of survival in continuous ambulatory peritoneal dialysis patients: The importance of prealbumin and other nutritional and metabolic markers. Am. J. Kidney Dis. 1994 23 : 91 8.
41. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N. Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. 2003 87 (Suppl S6 11.
42. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA. Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int. 2005 68 : 2794 800.
43. Goldwasser P, Michel MA, Collier J et al. Prealbumin and lipoprotein(a) in hemodialysis: Relationships with patient and vascular access survival. Am. J. Kidney Dis. 1993 22 : 215 25.
44. Mittman N, Avram MM, Oo KK, Chattopadhyay J. Serum prealbumin predicts survival in hemodialysis and peritoneal dialysis: 10 years of prospective observation. Am. J. Kidney Dis. 2001 38 : 1358 64.
45. Sreedhara R, Avram MM, Blanco M, Batish R, Avram MM, Mittman N. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am. J. Kidney Dis. 1996 28 : 937 42.
46. Rambod M, Kovesdy CP, Bross R, Kopple JD, Kalantar-Zadeh K. Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. Am. J. Clin. Nutr. 2008 88 : 1485 94.
47. Degoulet P, Legrain M, Reach I et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982 31 : 103 10.
48. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol. Dial. Transpl. 2006 21 : 2881 92.
49. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002 61 : 1887 93.
50. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J. Am. Soc. Nephrol. 2007 18 : 293 303. (Pubitemid 46053442)
51. Kalantar-Zadeh K, Kleiner M, Dunne E et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am. J. Kidney Dis. 1998 31 : 263 72.
52. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 1999 55 : 1945 51.
53. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 1990 15 : 458 82.
54. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int. 2002 62 : 2238 45.
55. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2004 44 : 661 71.
56. Wu DY, McAllister CJ, Kilpatrick RD et al. Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Clin. J. Am. Soc. Nephrol. 2006 1 : 70 78.
57. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007 15 : 1617 22.
58. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 2007 49 : 237 44.
59. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002 13 : 134 41.
60. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P. Low triiodothyronine and survival in end-stage renal disease. Kidney Int. 2006 70 : 523 8.
61. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin. Nephrol. 2009 29 : 3 14 (in press).
62. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 2008 121 : S388 92.
63. Hulsewe KW, van Acker BA, von Meyenfeldt MF, Soeters PB. Nutritional depletion and dietary manipulation: Effects on the immune response. World J. Surg. 1999 23 : 536 44.
64. Souba WW. Nutritional support. N. Engl. J. Med. 1997 336 : 41 8.
65. Alexander JW. Immunoenhancement via enteral nutrition. Arch. Surg. 1993 128 : 1242 5.
66. Kimmel PL, Phillips TM, Lew SQ, Langman CB. Zinc modulates mononuclear cellular calcitriol metabolism in peritoneal dialysis patients. Kidney Int. 1996 49 : 1407 12.
67. Erten Y, Kayatas M, Sezer S et al. Zinc deficiency: Prevalence and causes in hemodialysis patients and effect on cellular immune response. Transpl. Proc. 1998 30 : 850 51.
68. Casciato DA, McAdam LP, Kopple JD et al. Immunologic abnormalities in hemodialysis patients: Improvement after pyridoxine therapy. Nephron 1984 38 : 9 16. (Pubitemid 14090783)
69. Dobbelstein H, Korner WF, Mempel W, Grosse-Wilde H, Edel HH. Vitamin B6 deficiency in uremia and its implications for the depression of immune responses. Kidney Int. 1974 5 : 233 9.
70. DeSimone C, Famularo G, Tzantzoglou S, Trinchieri V, Moretti S, Sorice F. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: Effect of oral L-carnitine. AIDS 1994 8 : 655 60.
71. Jandacek RJ, Anderson N, Liu M, Zheng S, Yang Q, Tso P. Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am. J. Physiol. Gastrointest. Liver Physiol. 2005 288 : G292 9.
72. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am. J. Physiol. 1999 277 : E971 5.
73. Argiles JM. Cancer-associated malnutrition. Eur. J. Oncol. Nurs. 2005 9 (Suppl 2 S39 50.
74. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit. Care Med. 2007 35 : 849 55.
75. Rothenbach PA, Dahl B, Schwartz JJ et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J. Appl. Physiol 2004 96 : 25 31. (Pubitemid 38031978)
76. Christofidou-Solomidou M, Scherpereel A, Solomides CC et al. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J. Investig. Med. 2002 50 : 54 60. (Pubitemid 34098289)
77. Ziegler TR, Evans ME, Fernandez-Estivariz C, Jones DP. Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu. Rev. Nutr. 2003 23 : 229 61.
78. Pupim LB, Flakoll PJ, Ikizler TA. Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. J. Am. Soc. Nephrol. 2004 15 : 1920 26.
79. Pupim LB, Majchrzak KM, Flakoll PJ, Ikizler TA. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J. Am. Soc. Nephrol. 2006 17 : 3149 57.
80. Stratton RJ, Bircher G, Fouque D et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: A systematic review and meta-analysis. Am. J. Kidney Dis. 2005 46 : 387 405. (Pubitemid 41208174)
81. Czekalski S, Hozejowski R. Intradialytic amino acids supplementation in hemodialysis patients with malnutrition: Results of a multicenter cohort study. J. Ren. Nutr. 2004 14 : 82 8.
82. Feldt-Rasmussen B, Lange M, Sulowicz W et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J. Am. Soc. Nephrol. 2007 18 : 2161 71.
83. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 1999 281 : 1275 81.
84. Barton PA, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin. Nephrol. 2002 58 : 38 46. (Pubitemid 34752992)
85. Navarro JF, Mora C, Macia M, Garcia J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int. 2002 61 : 1537 44.
86. Galland R, Traeger J, Arkouche W, Cleaud C, Delawari E, Fouque D. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int. 2001 60 : 1555 60.
87. Galland R, Traeger J, Arkouche W, Delawari E, Fouque D. Short daily hemodialysis and nutritional status. Am. J. Kidney Dis. 2001 37 : S95 8.
88. Cano NJ, Fouque D, Roth H et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: A 2-year multicenter, prospective, randomized study. J. Am. Soc. Nephrol. 2007 18 : 2583 91.
89. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 1998 32 : 107 14.
90. Racki S, Zaputovic L, Mavric Z, Vujicic B, Dvornik S. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren. Fail. 2006 28 : 427 33.
91. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 55 : 648 58.
92. Ross R. Atherosclerosis - An inflammatory disease. N. Engl. J. Med. 1999 340 : 115 26.
93. Kovesdy CP, Kalantar-Zadeh K. Novel targets and new potential: Developments in the treatment of inflammation in chronic kidney disease. Expert Opin. Investig. Drugs 2008 17 : 451 67.
94. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 2001 59 : 1960 66.
95. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004 65 : 1009 16.
96. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ('carbonyl stress'). Kidney Int. 2001 78 (Suppl S25 31.
97. Nguyen-Khoa T, Massy ZA, De Bandt JP et al. Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol. Dial. Transpl. 2001 16 : 335 40.
98. Faggiotto A, Poli A, Catapano AL. Antioxidants and coronary artery disease. Curr. Opin. Lipidol. 1998 9 : 541 9.
99. Bayes B, Pastor MC, Bonal J et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol. Dial. Transpl. 2003 18 : 106 12.
100. Bayes B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis - Role of seniority and intravenous ferrotherapy: Analysis at 4 years of follow-up. Nephrol. Dial. Transpl. 2006 21 : 984 90.
101. Stenvinkel P, Diczfalusy U, Lindholm B, Heimburger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol. Dial. Transpl. 2004 19 : 972 6.
102. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am. J. Kidney Dis. 2005 45 : 39 47. (Pubitemid 40038043)
103. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 2000 356 : 1213 18.
104. Tepel M, van der GM, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 2003 107 : 992 5.
105. Wu MS, Yu CC, Yang CW et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol. Dial. Transpl. 1997 12 : 2105 10.
106. Morioka T, Emoto M, Tabata T et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001 24 : 909 13.
107. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am. J. Kidney Dis. 2002 40 : 566 75.
108. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year observational study. Diabetes Care 2006 29 : 1496 500.
109. Williams ME, Lacson E Jr., Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006 70 : 1503 9.
110. Tzamaloukas AH, Yuan ZY, Murata GH, Balaskas E, Avasthi PS, Oreopoulos DG. Clinical associations of glycemic control in diabetics on CAPD. Adv. Perit. Dial. 1993 9 : 291 4.
111. Tzamaloukas AH, Murata GH, Zager PG, Eisenberg B, Avasthi PS. The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J. 1993 39 : 880 85.
112. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association between glycemic control and mortality in diabetic patients with chronic kidney disease stage 1-5 not yet on dialysis. ]Abstract[. J. Am. Soc. Nephrol. 2007 18 : 573A.
113. Kalantar-Zadeh K, Kopple JD, Regidor DL et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007 30 : 1049 55.
114. Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic CKD patients: Where do we stand? Am. J. Kidney Dis. 2008 52 : 766 77.